The Human Medicines Regulations 2012 and research peptides

The Human Medicines Regulations 2012 (HMR) are the UK's main medicines law, and they are the reason research peptide suppliers speak the way they do. The regulations do not mention peptides; they define what a medicine is, require medicines to be authorised before sale, and control how they are advertised. Whether a research peptide falls inside them depends entirely on how it is presented and for what purpose. This note explains the relevant parts of the HMR for researchers and suppliers, in plain English. It is general information, not legal advice. All Alphex products are for laboratory and in-vitro research only.

What the HMR regulate

• Definition of a medicinal product (regulation 2): any substance presented as having properties for treating or preventing disease in humans, or that may be used in or administered to humans to restore, correct or modify physiological function, or to make a medical diagnosis.
• Marketing authorisation (Part 5): a medicinal product may not be sold or supplied without an authorisation from the MHRA, with limited exceptions (specials, clinical trials, and so on).
• Advertising (Part 14): controls on advertising medicines, and a prohibition on advertising unlicensed medicines to the public.
• Enforcement: the MHRA investigates and prosecutes unlawful sale, supply and advertising of medicines.

The two-limb definition, applied to research peptides

The definition has two limbs. Presentation: is the product presented as treating or preventing disease? A research peptide sold as a laboratory reagent, with chemistry and analytical data and no claims about people, is not. Function: is it to be administered to humans to modify physiological function? A research peptide sold for in-vitro and laboratory use is not. A product that fails either limb is not a medicinal product under the HMR and needs no marketing authorisation. That is the position of every product in the Alphex catalogue.

The same substance sold with claims about effects in people, or with dosing instructions, or in a form indicating administration, satisfies one or both limbs. It then becomes an unlicensed medicinal product, and its sale, supply and advertising are criminal offences. This is the line UK regulators police, and it is why suppliers who describe effects, dosing or "protocols" are the ones who receive enforcement attention.

What this means for a supplier

• Sell as a laboratory reagent, describe it as one, and be consistent everywhere.
• Make no therapeutic or physiological claims about humans, express or implied, including by testimonial or by linking to sources that make them in a way that adopts them.
• Provide no administration or dosing information for humans or animals.
• Restrict sale to research purposes and decline orders that indicate otherwise.

See what a compliant peptide listing looks like and MHRA and research peptides.

What this means for a researcher

Purchasing a research peptide as a laboratory reagent for laboratory work does not engage the HMR at all. The HMR would become relevant only if a researcher proposed to administer the substance to humans, at which point the clinical trials framework and MHRA authorisation apply and the research-grade material would in any case be unsuitable. Research using the material in vitro, or in licensed animal research under the Animals (Scientific Procedures) Act 1986, is governed by those separate frameworks. See can universities and labs buy research peptides.

Common misconceptions

• "If it's not licensed it must be illegal." No: unlicensed means it is not a medicine and may not be sold as one. It may be sold as a research reagent.
• "Research use only is a legal loophole." No: it is the accurate description of a lawful transaction. It becomes a problem only when it is untrue. See research use only: what it means.
• "Peptides are controlled drugs." The compounds in the Alphex catalogue are not listed under the Misuse of Drugs Act. See are research peptides legal in the UK.

Sources and further reading

• The Human Medicines Regulations 2012 (SI 2012/1916), legislation.gov.uk: the UK medicines framework; regulation 2 defines a medicinal product
• MHRA: A guide to what is a medicinal product (Guidance Note 8), GOV.UK: how the MHRA decides whether a product is a medicine by presentation and function
• Animals (Scientific Procedures) Act 1986, legislation.gov.uk: the framework governing licensed animal research

This note is general information and is not legal advice. Alphex research peptides are supplied for laboratory and in-vitro research by qualified researchers only. They are not authorised for human or veterinary use.

Research use only. Alphex products are supplied exclusively for laboratory and in-vitro research by qualified researchers. They are not authorised for human or veterinary use, and nothing in this note is advice on any such use.

Published 11 August 2026, last reviewed 16 August 2026. Alphex reviews research notes when the testing method, the catalogue or UK guidance changes.

Alphex Research Team

Alphex Limited, UK research peptide supplier

The Alphex research team writes and maintains these notes for UK laboratories buying research peptides. Every batch Alphex lists is verified by reverse-phase HPLC with a batch-matched Certificate of Analysis. Content covers laboratory and in-vitro research only.